Recombinant human interleukin-2(Beijing Ruide Hetong Pharmaceutical)

重组人白细胞介素-2（北京瑞得合通）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-2(Beijing Ruide Hetong Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsUrinary Bladder NeoplasmsLung NeoplasmsLiver Neoplasms +[8] 
Global Approved IndicationsUrinary Bladder NeoplasmsLung NeoplasmsLiver Neoplasms +[8] 
Approved Indications in ChinaUrinary Bladder NeoplasmsLung NeoplasmsLiver Neoplasms +[8] 
Original Approved Country/TerritoryMainland China
Original Approved Date2004/02/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Ruide Hetong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Ruide Hetong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsLung NeoplasmsLiver Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A